Edurant (Rilpivirine, TMC278)
| Brand Name: |
Edurant |
| Generic Name: |
Rilpivirine |
| Adult Single Dose: |
One 25-mg tablet taken once a day |
| Food & Liquid Restrictions: |
Take with meal |
| Drug Class: |
NNRTI |
|
|
|
The Basics
News & Research
- Studies on Pipeline ARVs: Quad, Evitegravir/Cobicistat, Cobicistat, GSK1265744, BMS986001 Dolutegravir, GSK-1265744, Long-Acting Formulations (Monthly Injections): Rilpivirine-LA, Raltegravir and Patient Views (May/June 2012)
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Similar Efficacy and a Few Gender-Related Differences in Side Effects With Rilpivirine Versus Efavirenz at 96 Weeks (January/February 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- Conference Update From IAS 2011: Medication News (September/October 2011)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- FDA Approve New NNRTI Rilpivirine (Edurant) in the U.S. (July/August 2011)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- Edurant and Sustiva Similar, With Some Failure and Safety Differences, in Two-Year Studies (July 21, 2011)
From AIDSmeds.com
- A New HIV Drug Called Edurant Gets Approved for First-Time Patients (May 20, 2011)
From Project Inform
- FDA Approves Edurant (Rilpivirine) for Use in Treatment-Naive Adults With HIV-1 (May 20, 2011)
From Tibotec Therapeutics
- Approval of Edurant (Rilpivirine), a New NNRTI, for the Treatment of HIV in Treatment-Naive Patients (May 20, 2011)
From U.S. Food and Drug Administration
- MSF Letter Criticizes Johnson & Johnson for Not Joining Medicines Patent Pool (April 26, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- Gilead Says FDA Won't Accept Filing for AIDS Pill (February 3, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Johnson & Johnson Deal May Bring HIV/AIDS Drugs to Developing Countries Faster (January 31, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- Gilead Sciences Receives "Refuse to File" Notification From U.S. FDA on New Drug Application for Single-Tablet Regimen of Truvada and TMC278 (January 25, 2011)
From Gilead Sciences, Inc.
- Rilpivirine: The New NNRTI on the Block (December 8, 2010)
Part of "Top HIV/AIDS-Related Clinical Developments of 2010," by David Wohl, M.D.
From TheBody.com
- Rilpivirine vs. Efavirenz (October 25, 2010)
To read PDF, click here.
In Treatment Update, from Canadian AIDS Treatment Information Exchange
- Update: 2010 International AIDS Conference (September/October 2010)
Tales from Vienna: The world's AIDS community converges upon Vienna for the International AIDS Conference.
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- TMC-278 Phase 3 ECHO/THRIVE Studies Resistance Profile Rilpivirine (September 15, 2010)
From National AIDS Treatment Advocacy Project
- Rilpivirine Shows Potent Activity (Summer/Fall 2010)
To read PDF, click here.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- TMC278 (Rilpivirine) Stands Up to Efavirenz in Battle of First-Line NNRTIs; FDA Approval May Be Drawing Near: A Blog Entry by Myles Helfand (July 28, 2010)
In The XVIII International AIDS Conference, from TheBodyPRO.com
- TMC278 Noninferior to Efavirenz in Naive But With More Virologic Failures (July 22, 2010)
From National AIDS Treatment Advocacy Project
- Peering in the Pipeline (Summer 2009)
To read PDF, click here.
In Achieve, from ACRIA and GMHC
- Drug Watch: Nanotechnology for Antiretroviral Delivery (Winter/Spring 2009)
To read PDF, click here.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Once-a-Month HIV Therapy: Could Nanotechnology Be the Next Treatment Frontier? (April 2008)
A simple explanation of new research on the use of nanotechnology in HIV treatment.
To read PDF, click here.
In Project Inform Perspective, from Project Inform
- Drug Watch: Next-Generation NNRTIs: Etravirine and Rilpivirine (Winter 2008)
To read PDF, click here.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- An Alternative NNRTI, TMC278, Progresses in Development (February 28, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- NNRTIs: The Next Generation Approaches (Part I) (December 14, 2006)
From TheBodyPRO.com
- New Drugs From Old Classes (Spring 2006)
A listing of NNRTIs, NRTIs and protease inhibitors currently in development.
To read PDF, click here.
In ACRIA Update, from AIDS Community Research Initiative of America
- NNRTIs in Development (March 30, 2006)
An overview from Edwin DeJesus, M.D.
From TheBody.com
|
Advertisement
|
Email
Glossary
